| Name | Aliskiren hemifumarate |
| Description | Aliskiren hemifumarate (CGP60536B) is an orally active nonpeptide renin inhibitor with antihypertensive activity. |
| Kinase Assay | Radioligand Binding Assay: Human CB1 and CB2 stably transfect HEK 293 cells and cell membrane is purified. 0.2-8 μg of the purified membrane is incubated with 0.75 nM [3H] CP55,940 and Rimonabant in the incubation buffer (50 mM Tris-HCl, 5 mM MgCl2, 1 mM EDTA, 0.3%BSA, pH 7.4). The non-specific binding is defined in the presence of 1 μM of CP55,940. The reactions are incubated for one and a half hours at 30 °C in Multiscreen. The reactions are terminated by manifold filtration and washed four times with ice-cold wash buffer (50 mM Tris, pH 7.4, 0.25% BSA).The radioactivity bound to the filters is measured by Topcount. The IC50 is determined as the concentration of Rimonabant required to inhibit 50% of the binding of [3H] CP55,940 and calculated by non-linear regression. |
| In vitro | Aliskiren hemifumarate appears to bind to both the hydrophobic S1/S3-binding pocket and to a large, distinct subpocket that extends from the S3-binding site towards the hydrophobic core of renin. Oral bioavailability of Aliskiren hemifumarate is 2.4% in rats, 16% in marmosets and about 2.5% in humans. [2] |
| Storage | Pure form: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 93 mg/mL (76.25 mM), Sonication is recommended.
H2O : 92 mg/mL (75.43 mM), Sonication is recommended.
Ethanol : 93 mg/mL (76.25 mM), Sonication is recommended.
|
| Keywords | SPP-100 | SPP100 | SPP 100 hemifumarate | Renin | Inhibitor | inhibit | Hypertension | colon carcinoma | CGP60536B hemifumarate | CGP-60536 | CGP60536 | CGP 60536 hemifumarate | cardiovascular diseases | cancer | cachexia | C26 | Autophagy | Aliskiren hemifumarate | Aliskiren |
| Inhibitors Related | Stavudine | Aceglutamide | Hemin | Tamoxifen | Cysteamine hydrochloride | Guanidine hydrochloride | Hydroxychloroquine | Paeonol | Naringin | Alginic acid | Diisononyl phthalate | Sildenafil citrate |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | NO PAINS Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Orally Active Compound Library | Bioactive Compounds Library Max | Anti-COVID-19 Compound Library | Anti-Metabolism Disease Compound Library | Anti-Cancer Drug Library |
United States
